Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer.

In conclusion, a novel and efficacious SMEDDS formulation containing LyP-1 with a droplet size less than 100 nm was developed for the lymphatic targeting of breast cancer.
PMID: 30660694 [PubMed - as supplied by publisher]

Source: European Journal of Pharmaceutics and Biopharmaceutics - January 17, 2019 Category: Drugs & Pharmacology Authors: Timur SS, Yöyen-Ermiş D, Esendağlı G, Yonat S, Horzum U, Esendağlı G, Neslihan Gürsoy R Tags: Eur J Pharm Biopharm Source Type: research